ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by iLeukon Therapeutics, Inc., now recruiting.
Overview
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07452224 by iLeukon Therapeutics, Inc., with 80 participants planned, started 2026-06-29 and due to reach its primary completion in 2029-06. Interventions recorded: ILKN421H, Pembrolizumab. Conditions listed: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Setting
An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Sponsor
iLeukon Therapeutics, Inc.
Registry
Enrolled
80